
-
UK probes maternity services after scandals
-
Asian countries most vulnerable to Strait of Hormuz blockade
-
Anger as Kanye West to perform in Slovakia after Hitler song
-
Israel targets Iran Guards, Tehran prison in fresh wave of strikes
-
Star-packed, Covid-shaped 'Death Stranding 2' drops this week
-
IOC is in 'best of hands', says Bach as he hands over to Coventry
-
Oil prices seesaw as investors await Iran response to US strikes
-
Beijing issues weather warning for hottest days of year
-
Tehran hit by Israeli attacks, vows response to US strikes
-
New CEO of Jeep owner Stellantis starts with leadership shake-up
-
Russian drone and missile barrage kills eight in Kyiv
-
Oil dips, dollar firms after US strikes in Iran
-
Paris Olympics and Paralympics cost taxpayer nearly 6 bn euros: state body
-
Eurozone business activity almost flat again in June
-
In Norway's Arctic, meteorologists have a first-row seat to climate change
-
Iran vows retaliation for US strikes as Israel keeps up attacks
-
Russian drone and missile barrage on Kyiv kills seven
-
Oil rises, dollar firms after US strikes in Iran
-
'Noble to attend': Budapest prepares for 'banned' Pride march
-
Art market banking on new generation of collectors
-
Turning 80, UN faces fresh storm of doubts
-
'A great start': NBA crown just the beginning for Shai
-
Man City hit six to reach Club World Cup last 16, Real Madrid win with 10 men
-
Iran vows retaliation after US strikes on nuclear sites
-
'Massive' Russian attack on Kyiv kills at least five: Ukraine
-
Groundbreaking Vera Rubin Observatory reveals first images
-
Thunder beat Pacers in game seven, cap stunning season with NBA crown
-
Pacers 'hearts dropped' after Haliburton injury: Carlisle
-
Ukraine says 'massive' Russian attack on Kyiv
-
Thunder's Gilgeous-Alexander named NBA Finals MVP
-
Thunder beat injury-hit Pacers in game seven to win NBA title
-
Oil prices spike after US strikes on Iran
-
Man City demolish Al Ain to reach Club World Cup last 16
-
Thunder beat Pacers to clinch first NBA Finals crown
-
Bone collectors: searching for WWII remains in Okinawa
-
Madrid coach Alonso says Rudiger complained of racist insult in Club World Cup win
-
Girls shouldn't shout?: Women break the mould at French metal festival
-
Indian activists seek to save child brides
-
Jonathan Anderson set for Dior debut at Paris Fashion Week
-
Ukraine says 'massive' Russian drone attack on Kyiv
-
Oasis: from clash to cash
-
Toxic threat from 'forever chemicals' sparks resistance in Georgia towns
-
All Blacks name five debutants in squad for France Tests
-
Pacers' Haliburton hurt early in game seven against Thunder
-
Suicide attack on Damascus church kills at least 22
-
French police probe fake Disneyland 'marriage' with nine-year-old
-
LQR House Announces Upcoming Strategic Marketing Collaboration With Whiplash Whiskey Ahead of Summer Launch
-
Geneva, Switzerland Set to Host World of Coffee Welcoming Thousands of Specialty Coffee Professionals and Enthusiasts
-
Dateline Resources Reports Strong Progress in Colosseum Gold-REE Exploration Program in California
-
Jerash Holdings Reports Financial Results for Fiscal 2025 Fourth Quarter and Full Year

DEA Blocks MMJ FDA Cannabis Research While Tribal Marijuana Transit Networks Operate in N.C. Unchecked
Watch the Senate hearing: https://dai.ly/x9j0le4
Despite MMJ's full regulatory compliance and orphan drug status from the FDA, its DEA manufacturing registration (GROW MARIJUANA) remains stonewalled inside a DEA administrative court system now deemed unconstitutional under Axon and Jarkesy. Meanwhile, tribal transit networks face virtually no enforcement-exposing a hypocritical and dangerous DEA double standard.
WASHINGTON, DC / ACCESS Newswire / June 23, 2025 / The U.S. Drug Enforcement Administration (DEA) continues to obstruct legally compliant cannabis research for debilitating conditions like Multiple Sclerosis (MS) and Huntington's Disease (HD)-even as marijuana distribution networks tied to tribal transit operations in North Carolina move quantities of cannabis across state lines with little to no DEA enforcement.

MMJ BioPharma Cultivation, a Rhode Island-based biopharmaceutical company, has 2,375 days working with the FDA and the DEA to bring to market a pharmaceutical-grade cannabinoid soft gelatin capsule for patients in need. Despite holding orphan drug designation from the FDA and full compliance with the Controlled Substances Act, MMJ's bulk manufacturing registration remains unjustifiably denied.
"While MMJ has followed every rule, built an FDA-compliant supply chain, and worked transparently with regulators, the DEA has chosen to prioritize obstruction over innovation," said Duane Boise, CEO of MMJ BioPharma. "Meanwhile, tribal-linked transit networks not subject to proper DEA scrutiny are distributing untaxed and unregulated marijuana across the country. Where is the oversight?"
A recent senate video investigation (Watch here) highlights how certain non-tribal operators have exploited tribal land and transportation frameworks to move illicit marijuana across state boundaries, posing regulatory and public safety concerns.
By contrast, MMJ's project has been frozen within a DEA administrative law court system now widely viewed as unconstitutional following Supreme Court decisions in Axon v. FTC and Jarkesy v. SEC. In February 2025, the Department of Justice itself abandoned its defense of the DEA's ALJ system, admitting it violates the separation of powers under Article II.
"DEA leadership has failed in its duty to distinguish between unlawful trafficking and lawful, science-based medicine," said Boise. "Patients suffer while the agency hides behind bureaucracy and political gamesmanship."
About MMJ BioPharma Cultivation
MMJ BioPharma Cultivation is a federally compliant cannabis research and manufacturing company working to bring cannabinoid-based therapies through FDA approval for rare and serious neurological diseases.
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
A.Mahlangu--AMWN